“…The right to withdraw from a XTx clinical trial may not be the only ethical issue that an IRB will face. Questions regarding risk‐benefit assessment, 28 patient selection criteria that are equitable, 29 and how to achieve true voluntary consent may arise 30,31 . Furthermore, one risk that may need to be assessed on an ongoing basis alongside the regular renewal of the clinical trial (on an annual basis or the timeline required by the institution) would be adherence to transplantation medicines, for example, immunosuppressive drugs.…”